Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Best use yet for electronic toys: Easing treatment-related pain for children with cancer

May 5, 2010
By Lois Wingerson
Article

Most of the youngest Americans have viewed IPods and video games as essentials for many years. Yet their use to distract kids with cancer from their pain is still in beta testing.

For a child with cancer, an introduction to the pediatric oncology unit usually entails undergoing many procedures in quick succession. One study has shown that for these children pain associated with interventions is twice as common as the pain from the disease itself. Just as for adults who have cancer, experiencing pain is one of their greatest fears.

All of this being the case, you'd think medical science would have an intense focus on alleviating procedure-related pain in pediatric oncology, using the best tools at our disposal. But while children with cancer may play on their Wii after they get home, so far there's little solid evidence for the effectiveness of virtual reality or even ordinary video games to distract them during treatment.

Children's hospitals are using them nonetheless. At the cancer clinic in Texas Children's Hospital (a leader in exploring pain management techniques), among other strategies such as live performers, positioning for comfort, and medication, children have the benefit of hand-held video games to distract them from pain and anxiety, says child life specialist Breanna Hopkins. The clinic is in the process of installing Wii systems as well.

As electronic toys are booming in variety and popularity, only now has a randomized study evaluated the simple procedure of letting children listen to an iPod (as I myself always do at the dentist) before and during lumbar puncture for leukemia, and then asking them about the experience afterwards.

The study appears this month in the Journal of Pediatric Oncology Nursing.

Two years ago, a Cochrane Collaboration systematic review determined that only 3 kinds of noninvasive interventions have shown promise for reducing children's pain associated with procedures that involve needles: cognitive behavior therapy, hypnosis, and "distraction." The first two interventions (as well as the invasive kind) require considerable time, effort, and training for medical personnel. Use of an iPod, in contrast, is something about which an American child might actually instruct an oncologist.

Oncology nurse Than Nahn Nguyen of the National Hospital of Pediatrics in Hanoi approached Stefan Nilsson of Sweden to collaborate, because of his prior research testing "music medicine" and virtual reality for cancer-related pain in children. The Hanoi study involved 40 children with leukemia who had all had lumbar puncture previously.

This time, they got no other form of pain relief than music-if that. All were given headphones, but only half were randomized (by choosing a slip of paper) to hear music through them. The lucky half were given iPods and shown how to use them, selecting their own playlist. The music began 10 minutes before the procedure did. Afterwards, 20 were interviewed with open-ended questions.

Those in the iPod group scored significantly lower for pain, heart rate, respiratory rate, and anxiety. Some said afterwards that they didn't even notice when the injection began. Both groups wanted to hear music the next time around.

“I didn’t feel any pain," said one child in the iPod group, adding with a smile: "The last time, I had to hold my mother’s hand very tightly…I didn’t need to do that this time." Children in the control group called the procedure "very painful" and spoke of anxiety, a sense of chaos, and fear of death.
Music has a venerable record as a form of distraction. There's less experience with using virtual reality, which involves many technical issues and can be quite complicated.

Nilsson, who is a pain management nurse at The Queen Silvia Children's Hospital in Goteborg, has tested a 3D virtual reality game involving a hunt for diamonds in an amusement park, experienced via headset and remote control. The team created it from off-the-shelf software and tested it in a randomized controlled trial involving 42 children and adolescents with cancer, before and during  venous punctures or the installation of subcutaneous venous ports.

The subjects in this study did not get to choose their own entertainment, which may be a problem: Some of them (especially boys) called the game "corny," although most would choose to play it again because they all found it "distracting." There was no significant difference between the groups in self-reported measures of pain, although nurses scoring an objective scale noticed fewer visual or motor signals of pain during venipuncture. The researchers note that none of the subjects experienced intense pain; all had also received cold spray or lidocaine and prilocaine before the procedure.

Perhaps a more useful result from the study reported in European Journal of Oncology Nursing was that most subjects neither noticed nor cared about the 3D component. This could dispense with the headset. Something on a flat computer screen could be just as effective, especially if the patient could choose the game. In fact, any game a kid enjoys might work, as long as it doesn't involve much arm movement. This all needs to be tested further, of course.

Nilsson says he hasn't "yet" approached game manufacturers about further research or perhaps about donating video games to pediatric oncology units, but he's attracted to the idea. Short of that, even in the current economy, the outright purchase of a few iPods and a few dozen tracks might not be out of the question for a cancer hospital.

One might hazard a guess that the young patients would approve. During the post-procedure interview, one child in the Hanoi study asked about the next procedure. "Will I be able to listen to music, or not?"

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
young person with cancer
uterus
Related Content
Advertisement

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.


FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

Tim Cortese
May 16th 2025
Article

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.


Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.


Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

FDA Approves Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
December 18th 2024
Article

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.


The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.


Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Opaganib Earns FDA Orphan Drug Status in Neuroblastoma

Russ Conroy
August 27th 2024
Article

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Related Content
Advertisement

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.


FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

Tim Cortese
May 16th 2025
Article

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.


Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.


Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

FDA Approves Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
December 18th 2024
Article

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.


The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.


Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Opaganib Earns FDA Orphan Drug Status in Neuroblastoma

Russ Conroy
August 27th 2024
Article

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.